Omega Therapeutics announced the addition of Jennifer Nelson, Ph.D., to the Company’s executive leadership team in the role of Senior Vice President, SVP, of Research. She brings over 20 years of experience working with RNA- and DNA-based therapies and technologies, and extensive expertise as a leader in building novel platforms. Prior to joining Omega, Dr. Nelson served as Vice President of Research at Flagship Pioneering
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OMGA:
- Omega Therapeutics Announces Jennifer Nelson, Ph.D., as Senior Vice President of Research
- Omega Therapeutics price target lowered to $6 from $7 at Chardan
- Omega Therapeutics reports Q2 EPS (30c), consensus (36c)
- Omega Therapeutics Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress
- Omega Therapeutics announces election of Richard Kender to its board